ENTRESTO is available in 3 dosage strengths1

Pills shown not actual size.
How to prescribe ENTRESTO to your adult patients
Choose initial dose of ENTRESTO based on current treatment and titrate to the target dose1
SWITCHING FROM A LOWER DOSE OR NOT CURRENTLY ON AN ACEi OR ARB1:

-
Low-dose ACEi: total daily dose of ≤10 mg of enalapril or therapeutically equivalent dose of another ACEi (eg, lisinopril ≤10 mg; ramipril ≤5 mg)2
-
Low-dose ARB: total daily dose of ≤160 mg valsartan or therapeutically equivalent dose of another ARB (eg, losartan ≤50 mg; olmesartan ≤10 mg)2
SWITCHING FROM A HIGHER DOSE OF AN ACEi OR ARB1:

-
High-dose ACEi: total daily dose of >10 mg of enalapril or therapeutically equivalent dose of another ACEi (eg, lisinopril >10 mg; ramipril >5 mg)2
-
High-dose ARB: total daily dose of >160 mg valsartan or therapeutically equivalent dose of another ARB (eg, losartan >50 mg; olmesartan >10 mg)2
-
ENTRESTO is contraindicated with concomitant use of an ACE inhibitor and in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy1
-
Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the angiotensin II receptor blocker valsartan1
ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin ‖ receptor blocker.
Unless your patient is on a high ACEi/ARB dose, start ENTRESTO at 24/26 mg twice daily and double the dose every 2 to 4 weeks, as tolerated by the patient. When switching from ACEi, be sure to allow for a 36-hour washout period prior to initiating ENTRESTO.1
DOSING IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT
How to prescribe ENTRESTO for severe renal impairment (eGFR <30 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh B classification)1

-
No starting dose adjustment is needed for mild or moderate renal impairment
-
No starting dose adjustment is needed for mild hepatic impairment. Use in patients with severe hepatic impairment is not recommended
-
ENTRESTO is contraindicated with concomitant use of an ACEi. Do not administer within 36 hours of switching from or to an ACEi

Discover support and resources to help get your
patients started on ENTRESTO
* In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1